36 results about "Nasal Drops" patented technology

This invention provides a quality testing method for nasal drops used to treat allergic rhinitis, belonging to the field of pharmaceutical testing. Specifically, it includes the following steps: S1. Preparing a test solution; S2. Preparing a mixed reference solution; S3. Separately sampling the reference solution and the test solution for analysis; S4. Generating a reference fingerprint chromatogram. This invention can present all different types of components of the medicinal materials on a single chromatogram through a single test, allowing for simultaneous determination of multiple components and achieving comprehensive and accurate quality control of Artemisia annua and Scutellaria baicalensis nasal drops. The quality assessment method provided by this invention has optimized chromatographic conditions and undergone methodological validation, possessing the advantages of method stability, good repeatability, and stable and reliable test results.

The invention discloses a nano drug-loaded nasal spray composition for treating nasosinusitis. The nano drug-loaded nasal spray composition is prepared from the following raw materials: nano silver, PVP (Polyvinyl Pyrrolidone), baicalin, flos magnoliae volatile oil, chitosan, PLGA (Poly (Lactic-co-Glycolic Acid), sodium hyaluronate, a citrate buffer solution and the balance of sterile normal saline. The invention also discloses a preparation method of the nano drug-loaded nasal spray composition for treating nasosinusitis, the preparation method comprises the following steps: firstly preparing PVP modified nano silver suspension, then preparing baicalin nanoparticles and magnolia flower volatile oil nanoparticles by adopting an emulsification-solvent evaporation method, and PVP is used as a stabilizer of nano silver to ensure the long-term dispersion stability of nano silver, so that the stability of the nano silver is ensured, and the stability of the nano silver is ensured. Finally, all the components are mixed in a sterile operation table, the pH is adjusted, filtration sterilization is conducted through a 0.22-micron sterile filter membrane, terminal sterilization is conducted through gamma-ray irradiation after split charging is conducted, and the final product can be prepared into quantitative spray or sterile nose drops to meet different clinical requirements.

The invention relates to the technical field of biological medicine, in particular to centipeda minima extracellular vesicle nose drops and a preparation method and application thereof.The centipeda minima extracellular vesicle nose drops comprise active ingredients, plant extracellular vesicles (Cm-EVs) derived from centipeda minima, the concentration of the plant extracellular vesicles (Cm-EVs) is 1 * 10 < 10 >-5 * 10 < 11 > particles / ml; the key active substances are as follows: the content of the Cm-EVs naturally encapsulated sesquiterpene lactone compound centipederin is more than or equal to 50 micrograms per milliliter (detected by HPLC-MS); the pharmaceutical auxiliary materials comprise 0.05 to 0.2 percent (w / v) of sodium hyaluronate, 0.8 to 1.0 percent (w / v) of NaCl and 0.005 to 0.02 percent (v / v) of polysorbate 80; the method has the beneficial effects that the targeted enrichment capability is realized: mucous membrane adhesion is enhanced through surface pectin protein, and the nasal cavity residence time is prolonged to 6 hours (the free medicine is less than 1 hour); the nano-scale particle size (80-200nm) can efficiently penetrate through the mucous layer, and the nasal mucosa drug concentration reaches 20 times of the plasma concentration (rat pharmacokinetic data); the long-acting slow-release property is as follows: the active ingredients are protected by the lipid bilayer, the cumulative release rate of the centipederin within 72 hours reaches 82%, and the free medicine can be completely released within 24 hours.

The application discloses application of a CGRP receptor small molecule antagonist in preparation of a medicine for treating chronic rhinosinusitis with nasal polyps. The medicine preparation is composed of an effective amount of the CGRP receptor small molecule antagonist and pharmaceutically acceptable adjuvants, and the dosage form is a nasal spray / drop / irrigation agent, and the administration route is simple and easy to operate, and is convenient for patients to use. The application can significantly reduce eosinophilic inflammation by inhibiting CGRP-mediated mast cell activation, and has a clear treatment advantage for eosinophilic nasal polyps. Compared with a biological preparation targeting type 2 cytokines, a small molecule compound is safer and simpler to obtain, can significantly reduce the treatment cost of patients, and provides a new efficient and economical choice for nasal polyp treatment.

1. Name of the designed product: medicine packing bottle (purple nose gel nasal drops). 2. Use of the designed product: for packing of purple nose gel nasal drops. 3. Design points of the designed product: in the combination of shape and pattern. 4. Picture or photo best indicating the design points: front view.

The utility model discloses a mouse nasal drop device which comprises a tube body and a liquid storage tube installed on the tube body. A dripping opening is formed in one end of the tube body, a supporting table is arranged in the tube body, and a through hole is further formed in the supporting table; one end of the liquid storage pipe is attached to the supporting table through an arranged sealing gasket, a liquid outlet hole is formed in the sealing gasket, and the sealing gasket is communicated with the through hole through the liquid outlet hole so that liquid in the liquid storage pipe can flow to the dripping opening. On the basis, the required dosage of nasal drop reagent is injected into the liquid storage tube and then dripped into the nasal cavity of the mouse through the dripping opening, so that compared with a pipette, the device has the advantages of convenience in operation and rapidness and convenience in liquid dripping, particularly, the dripping liquid is quantitatively measured, and the dripping opening is inserted into the nasal cavity, so that the nasal drop reagent is more convenient to use. Therefore, the problem that the test result is interfered by insufficient dropping liquid and outflow of the dropping liquid can be effectively solved.

The invention discloses a method for constructing a Yunnan pine pollen allergy animal model, which belongs to the technical field of Yunnan pine pollen allergy prevention and treatment and comprises the following steps: preparing Yunnan pine pollen allergens and sensitizing non-human mammals. The sensitization treatment comprises a basic sensitization treatment stage and an excitation sensitization treatment stage: in the basic sensitization treatment stage, peritoneal sensitization is carried out once a week and is continued for four weeks; in the nasal-drop sensitization treatment stage, different test substances with the concentration 2 times that of the basic sensitization stage are used for continuous 7-day quantitative nasal-drop excitation, and the nasal drop dosage is 2 microliters / g, and the symptoms of the mouse are observed within 10 minutes after nasal-drop excitation is completed each time. The allergic animal model constructed by adopting the crude extract of the pinus yunnanensis pollen allergen is the first animal model research related to pinus yunnanensis allergy at present, and a reference basis can be provided for subsequent experimental research on the aspect of deep research on pinus yunnanensis pollen allergy; a research model is provided for clinical research on the Yunnan pine pollen allergy or screening of medicines for resisting the Yunnan pine pollen allergy.

The invention discloses application of arginine vasopressin in treatment of slow transit constipation, and relates to the technical field of medicines for treating slow transit constipation. The arginine vasopressin nose drop is found to have a very good treatment effect on slow transit constipation for the first time, and especially for loperamide-induced slow transit constipation, the arginine vasopressin nose drop can effectively promote intestinal tract movement and improve constipation symptoms. The arginine vasopressin is prepared into nose drops, can bypass a blood brain barrier to enter the brain, directly targets downstream nuclei of AVP neurons in a hypothalamic para-ventricular nucleus PVN nuclei, and intervenes treatment in the nerve center, and the effect is better. The discovery of the invention expands a new application for arginine vasopressin drugs, and also provides a new idea for development of constipation drugs.

The invention relates to aqueous solutions containing a combination of lactoferrin with lactoperoxidase or with povidone iodine, encapsulated in liposomes, as active ingredients together with other components for use as nasal drops and nebulizers in combination with a mouth and face spray with antiviral, antiseptic and anti-inflammatory effects.

The invention discloses a mouse BHDS pulmonary focal degenerative pulmonary bullous model construction method and application, and the method comprises the following steps: adaptively feeding a healthy mouse for one week, then carrying out HCl injury treatment, and giving two microRNA fitting substances to the mouse twice in a nasal drop mode to obtain the BHDS pulmonary focal degenerative pulmonary bullous model. Expression changes of characteristic molecules in BHDS clinical sample lung tissues exist in the lung tissues of the model constructed by the invention, and the model is most suitable for BHDS-like lung tissue pathology so far. The invention provides a proper tool model for the effectiveness, safety and drug screening of BHDS pulmonary focal degenerative pulmonary bullous (BHD syndrome pulmonary cystic disease) treatment drugs, and ensures the repeatability and high efficiency of the model. Compared with a model constructed by gene knockout, the construction method provided by the invention is more stable in model formation, simpler and more convenient in operation method and experimental technology, and lower in cost.

The present invention belongs to the technical field of cancer immunotherapy and specifically relates to a combination-therapy drug and composition of a cholesterolylated TLR7 liposome and a TLR9 agonist and use thereof. Toll-like receptor agonists have poor targeting capability and significant side effects in anti-tumor treatment, and, as monotherapy in anti-tumor treatment, have limited efficacy. To address the described issues, the present invention provides the cholesterolylated TLR7 liposome, which is prepared from the cholesterol-modified 1V209 molecule 1V209-Cho, a lipid component, and cholesterol, and uses the liposome in combination with the TLR9 agonist to treat tumors. Animal results show that the combination of the liposome and the TLR9 agonist, when administered as nasal drops or by means of intramuscular injection, can significantly inhibit pulmonary metastasis of cervical cancer cells and melanoma cells, indicating that using the cholesterolylated liposome 1V209-Cho-Lip in combination with the TLR9 agonist to treat tumors is a strategy with great potential.

This invention provides a PND cyclodextrin inclusion complex, its preparation method, and its applications, relating to the field of pharmaceutical formulation technology. The method for preparing the PND cyclodextrin inclusion complex of this invention does not use organic solvents, is simple and easy to control, and has low cost. The technical solution of this invention greatly improves the solubility of PND in water, enhances the therapeutic effect of PND, and improves the stability of PND. This inclusion complex is suitable for preparing clinically required solid and liquid dosage forms, including infusions, injections, powder injections, oral solutions, novel nasal drops, nasal sprays, syrups, tablets, capsules, granules, and dispersible tablets. This inclusion complex can be used to prepare drugs for the prevention and treatment of influenza A virus infection.

The invention discloses an akabane virus challenge animal model and an establishment method and application thereof, and belongs to the technical field of animal models.According to the establishment method, a BALB / c mouse or a C57BL / 6N mouse is challenged in a nasal drop mode, so that an akabane virus challenge BALB / c mouse model or an akabane virus challenge C57BL / 6N mouse model is obtained, akabane virus liquid is adopted in the nasal drop mode, and the akabane virus liquid is adopted in the nasal drop mode. The akabane virus liquid is obtained from akabane viruses in an in-vitro cell culture mode, and the akabane virus strains are preferably GXLCH 16-70 strains; the akabane virus counteracting animal model constructed by adopting the method disclosed by the invention expands the universality of the akabane virus counteracting model on the week age and strain of the mouse, and is particularly applicable to model construction of the mouse with mature immune system; the obtained model has great application prospects in evaluating the effectiveness of akabane virus vaccines, screening akabane disease prevention drugs or screening akabane disease treatment drugs.

This invention relates to the field of plant-derived extracellular vesicles, and discloses a method for preparing and applying Hypericum perforatum-derived exosome-like nanovesicles (HPDENs). This invention prepares HPDENs with natural vesicle structures through a specific process, utilizing the natural characteristics of plant-derived vesicles to encapsulate Hypericum perforatum (…). HP The active ingredient, combined with nasal drops, achieves targeted delivery to the brain. It exerts its antidepressant effect by regulating microglia polarization imbalance and reshaping the "neuroimmune-synaptic" axis. This solves the core problems of traditional antidepressants, such as slow onset of action, poor treatment response, and large side effects. It can also improve the core pathological features of depression (neuritis, synaptic plasticity damage) and improve depressive-like behaviors, providing a brand-new option for the clinical treatment of depression.

This invention relates to an engineered mesenchymal stem cell exosome complex, comprising mesenchymal stem cell exosomes and siRNA loaded on the mesenchymal stem cell exosomes. The invention also relates to a nasal drop formulation comprising the aforementioned exosome complex, which can be used to prepare a drug for treating bronchopulmonary dysplasia. The complex and formulation of the present invention possess unique advantages such as enhanced therapeutic specificity through targeted gene silencing, stable pulmonary vascular pathological repair effects, and engineered targeted therapy.

The invention relates to the technical field of medicines, and relates to application of carvedilol in preparation of a novel coronavirus respiratory mucosa vaccine. The novel coronavirus respiratory mucosa vaccine is a vaccine which takes carvedilol as a unique immunologic adjuvant or a composite adjuvant containing capsaicin and is inoculated through a nasal drop or nasal spray way to prevent novel coronavirus infection. The recombinant new coronavirus spike protein is used as an antigen and is mixed with carvedilol, and the mixture is inoculated to a narla golden hamster in a nasal drop manner. Experimental results show that carvedilol can effectively promote a body to generate a specific antibody aiming at spike protein, so that the IgG level in serum is remarkably improved, and IgA response in alveolar lavage fluid is also enhanced. Therefore, a basis is provided for development of carvedilol as a respiratory mucosa vaccine adjuvant.

The present application relates to the technical field of traditional Chinese medicine. The purpose is to provide a traditional Chinese medicine hot compress for treating children's rhinitis, which comprises the following weight parts of traditional Chinese medicine raw materials: perilla seed 4-6 parts, radish seed 4-6 parts, white mustard seed 2-4 parts, xanthium 2-4 parts, cyperus 2-4 parts, asarum 1-2 parts, evodia 1-2 parts. The present application uses external application of medicine, the use mode is simple, and the patient compliance is high. Through precise proportioning of the prescription, the special prescription is suitable for special diseases, the force is special and one, and the chronic rhinitis patients can take the medicine for a long time, which is convenient, safe and reliable in curative effect. As a pure traditional Chinese medicine formula, its preparation and use are safer and more reliable than furazolidone and other hormone nasal drops in the treatment of rhinitis, and are green and safe.

The invention relates to a traditional Chinese medicine RNA / HKP nano preparation and pharmaceutical application thereof, the traditional Chinese medicine RNA / HKP nano preparation comprises (a) a tRNA fragment derived from ganoderma lucidum, the tRNA fragment is a double-stranded RNA molecule containing an antisense strand nucleotide sequence as shown in SEQ ID NO.1 and a sense strand nucleotide sequence as shown in SEQ ID NO.2, or a functional variant or homolog of the double-stranded RNA molecule; and (b) a pharmaceutically acceptable nano delivery carrier. The traditional Chinese medicine RNA / HKP nano-preparation is a nano-particle pharmaceutical preparation formed by self-assembly of tRFs fragments from ganoderma lucidum and a nano-drug delivery system carrying positive charges according to the mass ratio of 1: 3, and airway inflammation, airway mucus high secretion and airway remodeling can be effectively improved through nasal dripping local administration.

The invention provides an external traditional Chinese medicine composition for treating allergic rhinitis. The external traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 160 to 240 parts of paniculate swallowwort root, 36 to 54 parts of cicada slough, 0.24 to 0.36 part of borneol and 0.24 to 0.36 part of antrodia camphorata. The invention further provides a preparation method and application of the external traditional Chinese medicine composition. Pharmacodynamic tests prove that the medicinal effect of the traditional Chinese medicine composition is obviously superior to that of a prescription disclosed in the application number 201010238755.7, and the traditional Chinese medicine composition is more favorable for being prepared into a gel and exerts a better medicinal effect. The prepared external nasal drop can remarkably improve clinical symptoms of allergic rhinitis and is high in safety, meanwhile, the invention further provides a method for preparing the external nasal drop, and the method is simple in process and easy to produce.

1. Name of the product in this design: Automatic Poultry Immunization Machine. 2. Purpose of this design: Used for poultry immunization procedures, suitable for intramuscular injection, subcutaneous injection behind the neck, pterygium puncture vaccination, and ocular and nasal drops. 3. The key design feature of this product is its shape. 4. The picture or photo that best illustrates the key design points: Design 1 3D diagram 1. 5. Design 1 is designated as the basic design.

This invention discloses a method for constructing a mouse model of allergic rhinitis. The method includes the following steps: selecting BALB / c mice for feeding; sensitizing the mice by intraperitoneal injection of physiological saline containing casein, lactose, and aluminum hydroxide, once a day for 6-8 consecutive days; after the intraperitoneal injection is completed, administering physiological saline containing casein and lactose to the mice via nasal drops at intervals, once a day for 6-8 consecutive days, while simultaneously administering olive oil containing toluene diisocyanate to the mice via nasal drops during the intervals; this invention's method, by limiting each step and parameter, enables the rapid construction of a mouse model of allergic rhinitis, requiring only about two weeks. Furthermore, this invention's method is simple and easy to implement, with a high success rate and survival rate.

The application discloses a kind of nasal drops based on drug-loaded pollen for rhinitis and its preparation method and application, belong to the field of biomedical materials;The nasal drops include drug-loaded pollen microcarrier and pharmaceutically acceptable adjuvant;The drug-loaded pollen microcarrier is natural sunflower pollen particle with hollow cavity and surface thorn structure, and the cavity is loaded with the drug for treating allergic rhinitis.In the preparation method, sunflower pollen is washed, defatted with acetone diethyl ether, and treated with phosphoric acid cleavage to obtain pollen microcarrier with hollow outer thorn;Then, small molecule drugs are loaded under vacuum and reduced pressure;Finally, the adjuvant is mixed to prepare the drops.The application utilizes the natural "internal cavity and external thorn" structure of pollen, realizes efficient adhesion and sustained-release drug delivery in nasal cavity, and effectively resists cilia clearance.The pollen microcarrier removes allergenic proteins, has good biocompatibility, and does not aggravate allergic rhinitis.The application is low in cost and simple in operation, and provides a safe and efficient new platform for nasal drug delivery.

The invention belongs to the technical field of biology, and discloses a replication-deficient CAV2 recombinant virus for expressing a rabies virus ERA-G antigen gene, and the replication-deficient CAV2 recombinant virus is a recombinant canine type 2 adenovirus and is preserved in China Center for Type Culture Collection; the preservation date is March 13, 2024; the preservation number is CCTCC (China Center For Type Culture Collection) NO: The preservation address is Wuhan University, Wuhan, China. The recombinant virus has a good protection effect, is particularly suitable for nasal drip and intramuscular injection combined immunization, and can be efficiently rescued, propagated and passaged in a specific cell line. Meanwhile, the invention also provides a rescue method, a passage or propagation method and a vaccine of the recombinant virus as well as another replication-defective CAV2 recombinant virus and application of the replication-defective CAV2 recombinant virus.

This invention provides a poultry immunization device, comprising a body, a clamping unit and an eye / nasal drop unit disposed on one side of the bottom of the body, and an injection unit disposed on the other side of the bottom of the body. The injection unit is connected to the clamping unit and the eye / nasal drop unit via pipes. Protective shielding units are disposed on the surfaces of the clamping unit and the eye / nasal drop unit. A buffer storage compartment is disposed at the bottom of the clamping unit and the eye / nasal drop unit to temporarily store the immunized poultry. A control unit is disposed at the top of the body, and the control unit is signal-connected to the clamping unit, the injection unit, and the eye / nasal drop unit. The clamping unit facilitates operation, ensures accurate immunization injection, and provides a suitable clamping position for the poultry. Furthermore, it ensures high operational safety, as the poultry automatically moves up and down after being clamped, avoiding the risk of accidental injury to the operator.

The invention relates to the technical field of medicines, and relates to application of capsaicin in preparation of a novel coronavirus respiratory mucosa vaccine. The novel coronavirus respiratory mucosa vaccine is a vaccine which takes capsaicin as a unique immunologic adjuvant or a composite adjuvant containing capsaicin and is inoculated through a nasal drop or nasal spray way to prevent novel coronavirus infection. The recombinant new coronavirus spike protein is used as an antigen and is mixed with capsaicin, and then the mixture is inoculated to the narla golden hamster in a nasal drop manner. Experimental results show that capsaicin can effectively promote a body to generate a specific antibody aiming at spike protein, so that not only is the IgG level in serum remarkably improved, but also the IgA response in alveolar lavage fluid is enhanced. Therefore, a basis is provided for development of capsaicin as a respiratory mucosa vaccine adjuvant.

The embodiment of the application discloses a method for constructing a human respiratory syncytial virus newborn mouse infection model and application thereof.The method comprises the following steps: inoculating a virus liquid containing a human respiratory syncytial virus (RSV) into a 3-day-old SPF healthy BALB / c newborn mouse through nasal drops, and obtaining the human respiratory syncytial virus newborn mouse infection model after 4-5 days.The application successfully establishes a newborn mouse infection model which is simple to operate, good in repeatability and closer to clinical pathological characteristics.The model has the advantages of high virus infection rate, high similarity of pathological characteristics to human newborn infection, simple model construction method, short cycle, low cost, good stability and strong repeatability, and has a wide application prospect in RSV related research and development.

The invention relates to the technical field of pharmaceutical preparations, in particular to a nasal brain-entering drug delivery accelerator and application thereof, and the accelerator is glycerin and chemical derivatives, chemical isotope markers, condensation compounds or salts thereof. The composition specifically comprises triglyceride, glyceryl ether, glycerophosphate, glyceryl amino acid salt, glyceryl alcohol, glyceric acid, glyceryl acyl, glyceryl glycolate, glyceryl stearate, glycerol or mannitol and the like. The accelerant can be used for preparing nasal drops, and the mass fraction of the accelerant in the nasal drops is 0.01-40%. Experiments prove that the accelerant can significantly improve the intranasal absorption (P < 0.001) of active ingredients, so that the nose-brain delivery efficiency of drugs is effectively improved, the accelerant is expected to be applied to enhancing the curative effect of intranasal administration on central nervous system diseases, brain tumors and other diseases, and a new thought and method are provided for diagnosis of the diseases.

1. Name of the product in this design: Nasal Dropper. 2. Intended use of this design: for delivering fluid to the upper respiratory tract in the form of a spray or droplets to rinse the nasal cavity or administer medication. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The application discloses a preparation method of a nasal drop with traditional Chinese medicine biological components for treating rhinitis, and comprises the following steps: step one, preparing the first type of nasal drop: frying Semen Xanthii is matched with Magnolia and Bai Zhi to prepare the first type of nasal drop; step two, preparing the second type of nasal drop: using Mentha with Chrysanthemum and Forsythia to prepare the second type of nasal drop; step three, preparing the third type of nasal drop: matching Huangqi with Baishu and Fangfeng to prepare the second type of nasal drop; step four, preparing the finished product: mixing the prepared first type of nasal drop, the second type of nasal drop and the third type of nasal drop to obtain the finished product, wherein the raw materials of the nasal drop are all traditional Chinese medicines, the traditional Chinese medicine preparation has the characteristics of safety and reliability, easy purchase of raw materials, moderate price and easy production, and the traditional Chinese medicine preparation has the characteristics of broad-spectrum treatment of rhinitis, replacement of traditional hormone treatment, reduction of damage of the medicine to the human body and high safety.

This invention relates to the field of traditional Chinese medicine antibacterial liquid technology, and particularly to a traditional Chinese medicine antibacterial liquid for nasal use, made from the following raw materials: Xanthium sibiricum, Centipeda minima, Magnolia biondii, Asarum heterotropoides, Acorus tatarinowii, Akebia trifoliata, Atractylodes lancea, Indigo naturalis, Mentha haplocalyx, and polyhexamethylene biguanide. This invention combines nine traditional Chinese medicines—Xanthium sibiricum, Centipeda minima, Magnolia biondii, Asarum heterotropoides, Acorus tatarinowii, Akebia trifoliata, Atractylodes lancea, Indigo naturalis, and Mentha haplocalyx—with polyhexamethylene biguanide. The traditional Chinese medicine components are an improvement on the ancient formula of Xanthium sibiricum powder, synergistically exerting the effects of clearing the lungs and nasal passages, dispelling wind and cold, and anti-inflammatory and anti-allergic properties. Polyhexamethylene biguanide provides broad-spectrum antibacterial efficacy. By changing the traditional oral dosage form to a nasal drop, the liquid acts directly on the nasal mucosa lesion site, avoiding the first-pass effect of the liver and the metabolic burden on the kidneys associated with oral medications, significantly improving drug safety. Skin irritation, eye irritation, and allergy tests all showed no irritation or sensitization.